Omniferon is currently in Phase II clinical studies in Europe for hepatitis C.
Karen Brown, products development manager, Viragen (Scotland) Ltd., stated, "In combining Viragen's proprietary natural alpha-interferon, Omniferon, with Zonagen's formulation, we anticipate that the delivery of the drug across the skin layers will be enhanced, potentially giving a more effective treatment for this debilitating disease."
The collaborators will utilize PolyMASC's novel protoMASC PEGylation process to deliver Viragen's lead drug, Omniferon, a natural alpha interferon currently in Phase II clinical trials in Europe for hepatitis C.
Both companies believe that PolyMASC's proprietary PEGylation technology should improve Omniferon's efficacy while reducing the number of injection's required for the treatment of hepatitis C patients.
"The development of a PEGylated Omniferon using PolyMASC's novel technology keeps Viragen at the forefront of immunotherapy and fits perfectly into our clinical development plan for hepatitis C."
We believe PolyMASC has the most efficient PEGylation process available and we have every confidence that the evaluation stage for Omniferon will prove successful."
Viargen uses white blood cells as the source material for the manufacture of Omniferon
, its proprietary, multi-subtype, highly purified natural alpha interferon drug currently in preclinical studies.
(Plantation, FL) announced that it has filed patent applications covering the intellectual property developed for the production of its lead biopharmaceutical product Omniferon
, the company's second generation multispecies natural interferon alpha.